Vericel products remain available without interruption

The past few months have brought unprecedented challenges and stress to all Americans and others around the globe. At Vericel Corporation, our thoughts are with those affected by COVID-19 and we are especially thankful to all healthcare workers for their critical efforts during this challenging time.

Our mission to help treat patients with serious knee cartilage and burn injuries has remained steadfast throughout the pandemic. Vericel continues to manufacture MACI^® (autologous cultured chondrocytes on porcine collagen membrane) and Epicel^® (cultured epidermal autografts) for those in need of care. Vericel’s products are aseptically manufactured in an FDA licensed facility using sterile materials and reagents. Our clean rooms maintain the highest cleanliness standards through automated environmental controls and monitoring. A rotational cleaning program of the room and all work surfaces includes quality control testing and release of the rooms. All Vericel manufacturing personnel wear pre-sterilized gowning materials. Laminar flow biosafety cabinets located within the clean rooms are used for all manufacturing processes. Each phase of manufacturing is monitored and tested for microbial contamination. Following manufacturing, all final products undergo rigorous quality control testing including the use of numerous proprietary release assays to ensure that our products are safe, consistent, and free of microbial contaminants.

The health and safety of our employees and their families has remained our highest priority during continued operations. Vericel has set forth and continues to implement a multi-faceted workplace safety and response plan designed to protect our employees, partners, and customers from exposure to the COVID-19 virus, while continuing our mission to treat the patients we serve.